Castle Biosciences (Castle Biosciences) Interest Coverage

: 0 (At Loss) (As of Dec. 2023) 中文

View and export this data going back to 2019. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Castle Biosciences's Operating Income for the three months ended in Dec. 2023 was $-5.7 Mil. Castle Biosciences's Interest Expense for the three months ended in Dec. 2023 was $-0.0 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Castle Biosciences's Interest Coverage or its related term are showing as below:

CSTL's Interest Coverage is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 12.375
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Castle Biosciences Interest Coverage Historical Data

The historical data trend for Castle Biosciences's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Castle Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

1.60

Castle Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage																-	-	-	-	-

Competitive Comparison

For the Diagnostics & Research subindustry, Castle Biosciences's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Castle Biosciences Interest Coverage Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Castle Biosciences's Interest Coverage falls into.

Castle Biosciences Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Castle Biosciences's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Castle Biosciences's Interest Expense was $-0.0 Mil. Its Operating Income was $-68.0 Mil. And its Long-Term Debt & Capital Lease Obligation was $14.2 Mil.

Castle Biosciences did not have earnings to cover the interest expense.

Castle Biosciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Castle Biosciences's Interest Expense was $-0.0 Mil. Its Operating Income was $-5.7 Mil. And its Long-Term Debt & Capital Lease Obligation was $14.2 Mil.

Castle Biosciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Castle Biosciences (NAS:CSTL) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Castle Biosciences Interest Coverage Related Terms

Thank you for viewing the detailed overview of Castle Biosciences's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Castle Biosciences (Castle Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Castle Biosciences Inc (NAS:CSTL) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 S. Friendswood Drive, Suite 401, Friendswood, TX, USA, 77546

Website

https://www.castlebiosciences.com

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Executives

Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Derek J Maetzold	director, 10 percent owner, officer: Pres. & Chief Exec. Officer	820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Ellen Goldberg	director	C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Tiffany Olson	director	C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Kristen M Oelschlager	officer: Chief Operating Officer	C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Bernhard E. Spiess	officer: Chief Operating Officer	C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Kim Caple	director	C/O BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Frank Stokes	officer: Chief Financial Officer	C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Tobin W Juvenal	officer: Chief Commercial Officer	C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
David S Kabakoff	director, 10 percent owner	C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Cook Joseph C. Iii	director, 10 percent owner	C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, STE. 201, FRIENDSWOOD TX 77546
Mara G. Aspinall	director	7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Bonnie H Anderson	director	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mgc Venture Partners 2013 Gp, Llc	10 percent owner	C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203
Mgc Venture Partners 2013, L.p.	10 percent owner	C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203